Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
James Sulat Insider Profile
4 Followers
James Sulat, Director at Momenta Pharma, holds 53.12K shares in Mallinckrodt public limited company (Ticker: MNKTQ), holds 0.00 shares in Amag Pharmaceuticals (Ticker: AMAG), holds 1.75M shares in Arch Therapeutics (Ticker: ARTH).
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
-4.00%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that James Sulat holds in companies
Most Profitable Insider Trade
Stock:
Momenta Pharma
(MNTA)
(MNTA)
Rating:Informative Buy
Date:Oct 20, 2014 - Oct 20, 2015
Return:+39.50%
The most profitable trade made by James Sulat
James Sulat's Trading History
Momenta Pharma
Jun 27, 2016
―
Uninformative Buy
―
$2.84M
Arch Therapeutics
Jun 23, 2020
Director
Informative Buy
37.19B
$448.93K
Exicure
―
Director
―
―
Mallinckrodt public limited company
Jun 29, 2023
―
Uninformative Sell
4.04K
$6.37K
Amag Pharmaceuticals
Nov 17, 2020
―
Uninformative Sell
―
$0.00
diaDexus
―
―
―
―
RR Donnelley
―
―
―
$2.27K
Codexis
―
Director, Ten Percent Owner
―
$31.45M
Maxygen
―
―
―
―
List of latest transactions for each holding click on a transaction to see James Sulat's performance on stock
You May Also Like
James Sulat insider profile FAQ
What is the percentage of profitable transactions made by James Sulat?
The percentage of profitable transactions made by James Sulat is 50%.
What is the average return per transaction made by James Sulat?
The average return per transaction made by James Sulat is -4.00%.
What stocks does James Sulat hold?
James Sulat holds: MNTA, ARTH, XCUR, MNKTQ, AMAG, DDXSQ, RRD, CDXS, MAXY stocks.
What was James Sulat’s latest transaction?
James Sulat latest transaction was an Uninformative Sell of $4.04K.
What was James Sulat's most profitable transaction?
James Sulat’s most profitable transaction was an Informative Buy of MNTA stock on October 20, 2014. The return on the trade was 39.50%.
What is James Sulat's role in Momenta Pharma?
James Sulat's role in Momenta Pharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.